ALKS 7119
Alternative Names: ALKS7119Latest Information Update: 04 Mar 2017
At a glance
- Originator Alkermes plc
- Class Antidepressants; Nootropics
- Mechanism of Action NMDA receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Agitation
Most Recent Events
- 01 Oct 2016 Discontinued - Phase-I for Agitation (In volunteers) in Netherlands, USA (PO) due to unfavourable tolerability results (Alkermes plc 10-K, February 2017)
- 01 Oct 2016 Discontinued - Preclinical for Agitation in Ireland (PO) due to unfavourable tolerability results (Alkermes plc 10-K, February 2017)
- 28 Apr 2016 Alkermes plans a phase I multiple ascending dose study in Agitation (In volunteers) (NTR5956)